Literature DB >> 25644063

Immunophenotypic features by multiparameter flow cytometry can help distinguish low grade B-cell lymphomas with plasmacytic differentiation from plasma cell proliferative disorders with an unrelated clonal B-cell process.

Flavia G Rosado1, William G Morice, Rong He, Matthew T Howard, Michael Timm, Ellen D McPhail.   

Abstract

Highly sensitive flow cytometry studies may incidentally identify B cell clones when used to assess plasma cell clonality in bone marrows. Clinical history, which can help differentiate related clones (low grade B cell lymphoma with plasmacytic differentiation/LBCL-PD) from unrelated ones (plasma cell proliferative disorder (PCPD) with an unrelated B cell clone), is often unavailable in referred specimens. We sought to identify morphologic or phenotypic features that would help predict the significance of these clones in the absence of history. We included only cases with identical light chain B and plasma cell clones, as determined by 6-color flow cytometry with additional DNA ploidy analysis, in which the relationship between clones could be established by review of medical records. There were 26 cases; 18 were related (14 were Waldenstrom macroglobulinemia) and eight were unrelated (seven multiple myeloma). Features seen exclusively in LBCL-PD include CD19+/CD45+ clonal plasma cell phenotype (66·7%, P = 0·0022) and morphologic features such as paratrabecular bone marrow involvement, increased mast cells, and plasma cells surrounding B-cell nodules. Aneuploidy was identified exclusively in PCPD cases (75%, P = 0·000028). We conclude that CD19+/CD45+ clonal plasma cell phenotype and aneuploidy are useful in distinguishing related clones (LBCL-PD) from unrelated clones (PCPD).
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  B-cell lymphoma; Flow cytometry; plasmacytic differentiation

Mesh:

Substances:

Year:  2015        PMID: 25644063     DOI: 10.1111/bjh.13303

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

Review 1.  The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing.

Authors:  Steven H Swerdlow; Isinsu Kuzu; Ahmet Dogan; Stephan Dirnhofer; John K C Chan; Birgitta Sander; German Ott; Luc Xerri; Leticia Quintanilla-Martinez; Elias Campo
Journal:  Virchows Arch       Date:  2015-10-10       Impact factor: 4.064

2.  Simultaneous Manifestation of Chronic Myelomonocytic Leukemia and Multiple Myeloma during Treatment by Prednisolone and Eltrombopag for Immune-Mediated Thrombocytopenic Purpura.

Authors:  Masao Hagihara; Morihiro Inoue; Kenichiro Kodama; Tomoyuki Uchida; Jian Hua
Journal:  Case Rep Hematol       Date:  2016-08-14

3.  Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms.

Authors:  Qi Gao; Venkata Yellapantula; Maly Fenelus; Janine Pichardo; Lu Wang; Ola Landgren; Ahmet Dogan; Mikhail Roshal
Journal:  Mod Pathol       Date:  2018-02-05       Impact factor: 7.842

Review 4.  CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen.

Authors:  John J Schmieg; Jeannie M Muir; Nadine S Aguilera; Aaron Auerbach
Journal:  Curr Oncol       Date:  2021-12-04       Impact factor: 3.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.